3 May 2024 - The agenda for next week's PBAC meeting is now available. Robyn Ward's first meeting as the chair will hardly be a baptism of fire.

The PBAC will consider submissions for the following technologies:

• Aflibercept (Eylea HD) - new formulation (2 indications/patient populations). Rescheduled from the March 2024 meeting.
• Foslevodopa with foscarbidopa (Vyalev) - new combination product. Rescheduled from the July 2023 meeting.
• Respiratory syncytial virus vaccine (bivalent) (Abrysvo) - new vaccine (resubmission). Rejected at the March 2024 meeting.

Read PBAC agenda